Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial
文献类型：期刊论文
| 作者 | Li, Ning1; Zhu, Jianqing2; Yin, Rutie3; Wang, Jing4; Pan, Lingya5; Kong, Beihua6; Zheng, Hong7; Liu, Jihong8; Wu, Xiaohua9; Wang, Li10 |
| 刊名 | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
 |
| 出版日期 | 2022-11-01 |
| 卷号 | 18 |
| ISSN号 | 1743-7555 |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| 出版者 | WILEY |
| WOS记录号 | WOS:000871956500189 |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/130035]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 作者单位 | 1.Chinese Acad Med Sci & Peking UnionMed Coll, Nat Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China 3.Sichuan Univ, West China Univ Hosp 2, Key Lab Birth Defects & Related Dis Women & Child, Minist Educ, Chengdu, Peoples R China 4.Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China 5.Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing, Peoples R China 6.Shandong Univ, Qilu Hosp, Jinan, Peoples R China 7.Peking Univ Canc Hosp & Inst, Beijing, Peoples R China 8.Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China 9.Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China 10.Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Li, Ning,Zhu, Jianqing,Yin, Rutie,et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY,2022,18. |
| APA | Li, Ning.,Zhu, Jianqing.,Yin, Rutie.,Wang, Jing.,Pan, Lingya.,...&Wu, Lingying.(2022).Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial.ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY,18. |
| MLA | Li, Ning,et al."Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial".ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 18(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。